<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6232">
  <stage>Registered</stage>
  <submitdate>12/12/2016</submitdate>
  <approvaldate>12/12/2016</approvaldate>
  <nctid>NCT03005873</nctid>
  <trial_identification>
    <studytitle>A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee</studytitle>
    <scientifictitle>A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TLC599A2003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis of the Knee</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TLC599
Treatment: drugs - Normal Saline

Experimental: Low-dose test drug group (LD group) - 12 mg DSP with 100 µmol PL (1.0 mL)

Experimental: High-dose test drug group (HD group): - 18 mg DSP with 150 µmol PL (1.5 mL)

Placebo Comparator: Placebo group - 1.5 mL normal saline


Treatment: drugs: TLC599
Single dose via intra-articular injection

Treatment: drugs: Normal Saline
Single dose via intra-articular injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>WOMAC questionnaire pain sub-scale - The primary endpoint is to evaluate the change from baseline by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale at Week 12.</outcome>
      <timepoint>at Week 12 after dosing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC questionnaire - Change from baseline to Weeks 1, 4, 8, 12, 16, 20, and 24 in pain / function subscales of WOMAC.</outcome>
      <timepoint>at Weeks 1, 4, 8, 12, 16, 20, and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain score (VAS) - Change from baseline to Weeks 1, 4, 8, 12, 16, 20, and 24 in the patient rated visual analogue scale (VAS).</outcome>
      <timepoint>at Weeks 1, 4, 8, 12, 16, 20, and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>EuroQol-5 Dimension questionnaire - Change from baseline to Weeks 1, 4, 8, 12, 16, 20, and 24 in EuroQol-5 Dimension questionnaire.</outcome>
      <timepoint>at Weeks 1, 4, 8, 12, 16, 20, and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Usage of acetaminophen - Total consumption of acetaminophen at Weeks 1, 4, 8, 12, 16, 20, and 24.</outcome>
      <timepoint>at Weeks 1, 4, 8, 12, 16, 20, and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Treatment-Emergent Adverse Events - To evaluate the safety and tolerability of TLC599 by incidence of Treatment-Emergent Adverse Events reported by Investigators</outcome>
      <timepoint>up to 24 weeks after dosing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Main 

          1. Male or female patients, at least 50 years of age.

          2. Documented diagnosis of OA of the knee for at least 6 months

          3. The study knee has OA with Grade 2 to 3 severity based on the Kellgren Lawrence grades

          4. Patients with patient related visual analogue scale (VAS) score of 5.0 to 9.0 at
             baseline.

          5. Willing and able to comply with study procedures and provide written informed consent.

        Main</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients who received systemic corticosteroids within the last 30 days prior to
             dosing.

          2. Patients who use prohibited medications within 7 days prior to study drug
             administration or any pain control medication including acetaminophen within 48 hours
             prior to study drug administration.

          3. Patients who use prohibited medications other than acetaminophen and oral NSAIDs from
             screening visit to 7 days prior to study drug administration.

          4. Documented history and confirmed autoimmune disease

          5. History of post-traumatic knee arthritis, or evidence of intra articular bleeding of
             the study knee

          6. History of infective arthritis

          7. Unstable study knee joint

          8. Use of IA corticosteroid, hyaluronic acid, or other IA injection in the study knee
             within 3 months prior to the screening visit.

          9. A history of treated malignancy which is disease free for = 5 years prior to the
             screening visit

         10. Uncontrolled and unstable concurrent medical or psychiatric illness, that will
             jeopardize the safety of the patient

         11. Use of any chemotherapeutic or systemic immunosuppressant agents for inflammatory
             diseases within 6 months prior to the screening visit.

         12. Current use of anticoagulants, including warfarin, heparin, low molecular weight
             heparin, or dabigatran.

         13. Abnormalities of laboratory parameters as described below will qualify for exclusion:

               -  hemoglobin &lt; 8 g/dL;

               -  total white blood cell count &lt; 4000/ µL;

               -  serum bilirubin/ alanine aminotransferase/ aspartate aminotransferase &gt; 2 times
                  upper limit of normal (ULN) for the laboratory reference ranges;

               -  serum creatinine &gt; 2 times ULN for the laboratory reference range;

               -  serum uric acid &gt; ULN for the laboratory reference range;

               -  prothrombin time/International Normalized Ratio &gt; ULN for the laboratory
                  reference range.

         14. Contraindication to undergoing magnetic resonance imaging (MRI)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>16/03/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>72</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Genesis Research Services Pty Limited - Broadmeadow</hospital>
    <hospital>Pendlebury Clinic Private Hospital - Cardiff</hospital>
    <hospital>Footscray Hospital- Western Health - Footscray</hospital>
    <hospital>Royal North Shore Hospital - Sydney</hospital>
    <postcode> - Broadmeadow</postcode>
    <postcode>2285 - Cardiff</postcode>
    <postcode> - Footscray</postcode>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhwa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Taiwan Liposome Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is a Phase IIa, Randomized, Double blinded, Placebo controlled, Dose finding Study
      to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the knee.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03005873</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Renee Chih</name>
      <address />
      <phone>+886 2 26557377</phone>
      <fax />
      <email>renee@tlcbio.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>